Aims: Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer (NSCLC) have reported conflicting results on progression-free survival (PFS) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients. Here we report effectiveness and safety outcomes by age subgroup for patients with NSCLC in the ARIES observational cohort study. Materials and Methods: ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician's choice. Kaplan-Meier estimates were used to calculate medians and 95% confidence intervals for PFS and overall survival for patients aged <65, ≥65, <75 and ≥75 years. Results: In total, 1967 patients receiving first-line treatment with bevacizumab and chemotherapy were enrolled. The median PFS and overall survival values were 6.4 (95% confidence interval=6.0-6.8) and 14.2 (95% confidence interval=12.7-15.2) months for patients aged <65 years, respectively, and 6.8 (95% confidence interval=6.3-7.0) and 12.1 (95% confidence interval=11.4-13.1) months for patients ≥65 years, respectively. For patients <75 years, the median PFS and overall survival values were 6.6 (95% confidence interval=6.3-6.9) and 13.5 (95% confidence interval=12.6-14.5) months, respectively, and 6.6 (95% confidence interval=5.9-7.1) and 11.6 (95% confidence interval=10.0-12.5) months, respectively, for patients ≥75 years. Incidence proportions of bevacizumab-associated adverse events were generally similar across all age groups. Conclusions: Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC.
- Observational cohort study
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging